Astrazeneca (AZN) Receivables - Other (2016 - 2025)
Astrazeneca has reported Receivables - Other over the past 11 years, most recently at $2.0 billion for Q4 2025.
- Quarterly results put Receivables - Other at $2.0 billion for Q4 2025, up 27.74% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (up 27.74% YoY), and the annual figure for FY2025 was $2.0 billion, up 27.74%.
- Receivables - Other for Q4 2025 was $2.0 billion at Astrazeneca, up from $1.6 billion in the prior quarter.
- Over the last five years, Receivables - Other for AZN hit a ceiling of $2.0 billion in Q4 2025 and a floor of $1.6 billion in Q4 2024.
- Median Receivables - Other over the past 5 years was $1.7 billion (2022), compared with a mean of $1.7 billion.
- Biggest five-year swings in Receivables - Other: skyrocketed 41.47% in 2021 and later decreased 8.24% in 2022.
- Astrazeneca's Receivables - Other stood at $1.8 billion in 2021, then dropped by 8.24% to $1.7 billion in 2022, then fell by 1.21% to $1.6 billion in 2023, then decreased by 3.66% to $1.6 billion in 2024, then increased by 27.74% to $2.0 billion in 2025.
- The last three reported values for Receivables - Other were $2.0 billion (Q4 2025), $1.6 billion (Q4 2024), and $1.6 billion (Q4 2023) per Business Quant data.